University of Notre Dame

Notre Dame researchers to create material for new antimicrobial mask

2-Jun-2020 2:55 PM EDT, by University of Notre Dame

Newswise — Not long after the coronavirus pandemic began impacting the nation, hospitals and other health services began running into shortages of personal protective equipment such as face masks. Typical masks can help prevent the transmission of disease, but have a one-time use. Researchers at the University of Notre Dame are working to develop a new fabric for antimicrobial masks that could potentially be reusable.

Funded by the National Science Foundation through a Rapid Response Research (RAPID) grant, scientists and engineers are collaborating to translate existing water filtration technology to create a new fabric that will not only capture viruses, like the coronavirus, but also deactivate them.

“Our team previously created a proprietary composite nanofiber material for water filtration that we believed could be fairly easily translated and utilized to filter air. Once the pandemic hit, we began to think more critically about how we could make an air filtration material for face masks that not only meets a critical need for health care professionals, but improves them,” said Nosang Vincent Myung, the Keating Crawford Endowed Professor in Chemical and Biomolecular Engineering at Notre Dame and co-lead on the project.

Through a decade-long collaboration, Myung and David Cwiertny, professor of civil and environmental engineering at the University of Iowa, developed a new material that maximized water filtration performance while minimizing the cost. By using this material’s unique formula, the researchers will aim to mimic the pathogen-capturing process for air filtration as well as include a biocidal or antimicrobial function.

As a part of the team, Patrick O’Shaughnessy, professor of occupational and environmental health at the University of Iowa, will assess the efficiency of the material’s ability for capturing airborne particles. Additionally, Kyle Bibby, associate professor and the Wanzek Collegiate Chair in the Department of Civil and Environmental Engineering and Earth Sciences at Notre Dame, will utilize his expertise to test if it’s effective, and how successful the material is at deactivating airborne viruses.

“The water filter materials Nosang and I developed have always been hybrids — both blocking and reacting with molecules. Now we are looking forward to applying this same concept to a product that could protect people within the health services industry and those that may be exposed to other air-compromised environments,” said Cwiertny, co-lead on the project.

Myung and Bibby are affiliated with Notre Dame’s Advanced Diagnostics and Therapeutics initiative.




Filters close

Showing results

1120 of 4578
Released: 15-Jan-2021 1:30 PM EST
New England Journal of Medicine publishes COVID-19 treatment trial results
University of Texas at San Antonio

A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine.

Released: 15-Jan-2021 12:40 PM EST
DNA test can quickly identify pneumonia in patients with severe COVID-19, aiding faster treatment
University of Cambridge

Researchers have developed a DNA test to quickly identify secondary infections in COVID-19 patients, who have double the risk of developing pneumonia while on ventilation than non-COVID-19 patients.

Released: 15-Jan-2021 12:30 PM EST
Fight CRC To Present Research Findings on The Impact of COVID-19 on the Colorectal Cancer Community at 2021 GI ASCO
Fight Colorectal Cancer

Fight Colorectal Cancer presents abstract at Gastrointestinal Cancer Symposium highlighting the need to address the barriers and opportunities for care within the colorectal cancer community during the COVID-19 pandemic

Released: 15-Jan-2021 12:25 PM EST
Technion to Award Honorary Doctorate to Pfizer CEO Dr. Albert Bourla
American Technion Society

Israel's Technion will award an honorary doctorate to Pfizer CEO and Chairman Dr. Albert Bourla, for leading the development of the novel vaccine against SARS-CoV-2, the virus that causes COVID-19. The honorary doctorate will be conferred at the Technion Board of Governors meeting in November 2021.

Released: 15-Jan-2021 11:30 AM EST
UW researchers develop tool to equitably distribute limited vaccines
University of Wisconsin-Madison

Researchers at the University of Wisconsin School of Medicine and Public Health and UW Health have developed a tool that incorporates a person’s age and socioeconomic status to prioritize vaccine distribution among people who otherwise share similar risks due to their jobs.

Released: 15-Jan-2021 11:20 AM EST
Will Covid-19 kill the high street once and for all?
University of Sheffield

The shift to home working during Covid-19, or ‘Zoomshock’, threatens the survival of local goods and services provided in city centres and business parks

14-Jan-2021 5:00 PM EST
AACI Partners With Federal Vaccine Panel to Promote Cancer Patient Health
Association of American Cancer Institutes (AACI)

AACI was invited last summer to join the Vaccine Consultation Panel (VCP) alongside other leading health and science organizations in the U.S. Through the VCP, AACI has received periodic updates on the development and distribution of COVID-19 vaccines and participated in efforts to educate the cancer center community and the general public on the importance of widespread vaccine uptake.

Released: 15-Jan-2021 8:55 AM EST
The First Dose of the Pfizer Vaccine Gives About 50% COVID Protection, Not 91% Claimed by Those Who Want to Speed Up Immunization
Newswise

The NEJM paper actually states that the efficacy between the first and second doses was found to be 52 percent when given 21 days apart. After the second dose, the efficacy raises to 95 percent.

Released: 15-Jan-2021 8:20 AM EST
Houston Methodist study finds males of all ages more affected by COVID-19 than females
Houston Methodist

A new Houston Methodist study found males are more likely to test positive for COVID-19, have complications and die from the virus than females, independent of age. The peer-reviewed observational study appears in PLOS ONE, a multidisciplinary journal published by the Public Library of Science.

Released: 15-Jan-2021 8:20 AM EST
NIH Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19
Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)

NIH Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19 Ivermectin is Now a Therapeutic Option for Doctors & Prescribers


Showing results

1120 of 4578

close
1.25504